X4 Pharmaceuticals (XFOR)
(Delayed Data from NSDQ)
$0.64 USD
-0.07 (-10.13%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $0.64 0.00 (-0.50%) 7:46 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
XFOR 0.64 -0.07(-10.13%)
Will XFOR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for XFOR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for XFOR
What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock
All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy
XFOR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for XFOR
X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript
Stifel Nicolaus Keeps Their Buy Rating on X4 Pharmaceuticals (XFOR)
X4 Pharmaceuticals (XFOR) Gets a Buy from Piper Sandler
Buy Rating Affirmed on X4 Pharmaceuticals: A Comprehensive Analysis of Financial Stability and Drug Development Progress
X4 Pharmaceuticals Unveils Corporate Presentation for Investors